Benralizumab
- Product Name
- Benralizumab
- CAS No.
- 1044511-01-4
- Chemical Name
- Benralizumab
- Synonyms
- MEDI-563;BIW-8405;Benralizumab;BIW-8405|||MEDI-563;Benralizumab (anti-IL-5Ra);Research Grade Benralizumab;Research Grade Benralizumab(DHF86301)
- CBNumber
- CB55821388
- Formula Weight
- 0
- MOL File
- Mol file
Benralizumab Property
- storage temp.
- Store at 4°C, do not freeze
- solubility
- Soluble in DMSO
- form
- Liquid
- color
- Colorless to light yellow
N-Bromosuccinimide Price
- Product number
- CS-0069892
- Product name
- Benralizumab
- Purity
- ≥99.1%
- Packaging
- 1mg
- Price
- $2250
- Updated
- 2021/12/16
- Product number
- CS-0069892
- Product name
- Benralizumab
- Purity
- ≥99.1%
- Packaging
- 2mg
- Price
- $4100
- Updated
- 2021/12/16
Benralizumab Chemical Properties,Usage,Production
Uses
Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma[1].
in vivo
Benralizumab (MEDI-563) (0-30 mg/kg; i.v.; once every 3 weeks for 12 weeks) reduces peripheral blood and bone marrow eosinophil[2].
| Animal Model: | Female and male cynomolgus monkeys[2] |
| Dosage: | 0.1, 1, 10, and 30 mg/kg |
| Administration: | Intravenous injection, once every 3 weeks for 12 weeks |
| Result: | Blood eosinophil counts decreased close to the limit of detection after the first administration at all dose levels and remained undetectable. Eosinophil precursors in the bone marrow were reduced 80% or greater in all doses 3 days after the last administration (terminal necropsy) and remained undetectable until 18 days after the last dose in the 30 mg/kg group. The profound effect observed in the bone marrow was specific for the eosinophil lineage. |
IC 50
IL-5Rα
References
[1] Menzies-Gow A, et al. Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. ERJ Open Res. 2019 Sep 25;5(3). pii: 00009-2019. DOI:10.1183/23120541.00009-2019
[2] Kolbeck R, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010 Jun;125(6):1344-1353.e2. DOI:10.1016/j.jaci.2010.04.004
Benralizumab Preparation Products And Raw materials
Raw materials
Preparation Products
Benralizumab Suppliers
- Tel
- 27-027-83314682 13554138826
- Fax
- +86 (27) 8331-4682
- whsrtech@vip.163.com
- Country
- China
- ProdList
- 246
- Advantage
- 62
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Country
- United States
- ProdList
- 12952
- Advantage
- 65
- Tel
- 025-57798810
- Fax
- 025-57019371
- sales@sunlidabio.com
- Country
- China
- ProdList
- 3239
- Advantage
- 55
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- +86-0551-62678551 +86-15056975894
- Fax
- 05512678551
- sales@hirisunpharm.com
- Country
- China
- ProdList
- 176
- Advantage
- 55
- Tel
- 15971444841
- Fax
- 18327183813
- amber@biochempartner.com
- Country
- China
- ProdList
- 3061
- Advantage
- 58
- Tel
- 15911056312
- liming@bio-fount.com
- Country
- China
- ProdList
- 9729
- Advantage
- 58
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 0512-85557988 18662338937
- Fax
- 0512-85557182
- frank.wang@greature.com.cn
- Country
- China
- ProdList
- 147
- Advantage
- 58